Asset profile
Rosuvastatin
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Atherosclerotic Cardiovascular Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
Also in development:MASH / NASH · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
93 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 89 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Rosuvastatin: this drug | Approved | Small molecule | HMG-CoA reductase | ||
| Atovastatin | Phase 3 | Small molecule | HMG-CoA reductase | ||
| UIC201604 | Phase 3 | Small molecule | HMG-CoA reductase | ||
| Zhibitai | Phase 2 | Small molecule | HMG-CoA reductase | ||
| Monorova (Gemigliflozin) | Not yet studied | Small molecule | HMG-CoA reductase | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | ||
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor |
…and 78 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(47 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (14)
October 2026 (3)
Phase 1HealthyActive not recruiting
Est. primary completion 2026-10-14 · NCT07300280 · CT.gov ↗
What to watch
Early phase / not applicableAtherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2026-10-15 · NCT06603363 · CT.gov ↗
What to watch
Phase 1Cholesterol; LipidosisRecruiting
Est. primary completion 2026-10-30 · NCT04903223 · CT.gov ↗
What to watch
November 2026 (5)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2026-11-04 · NCT06772168 · CT.gov ↗
What to watch
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2026-11-07 · NCT07446400 · CT.gov ↗
What to watch
Phase 1HealthyNot yet recruiting
Est. primary completion 2026-11-10 · NCT07785830 · CT.gov ↗
What to watch
Phase 3CardiovascularNot yet recruiting
Est. primary completion 2026-11-10 · NCT07239414 · CT.gov ↗
What to watch
Phase 1ADPKD (Autosomal Dominant Polycystic Kidney Disease)Not yet recruiting
Est. primary completion 2026-11-15 · NCT07565441 · CT.gov ↗
What to watch
December 2026 (6)
Phase 1Overweight,ObesityRecruiting
Est. primary completion 2026-12-05 · NCT07550816 · CT.gov ↗
What to watch
Phase 1Overweight, ObesityActive not recruiting
Est. primary completion 2026-12-07 · NCT06982131 · CT.gov ↗
What to watch
Phase 1Lipid Profile,Blood PressureNot yet recruiting
Est. primary completion 2026-12-30 · NCT07389304 · CT.gov ↗
What to watch
Phase 1Diabete Mellitus, Lipid ProfileNot yet recruiting
Est. primary completion 2026-12-30 · NCT07378293 · CT.gov ↗
What to watch
Phase 4Statin Therapy, Statin Adverse Reaction, StatinRecruiting
Est. primary completion 2026-12-31 · NCT06804980 · CT.gov ↗
What to watch
Early phase / not applicableProstate Cancer, Cardiovascular DiseaseActive not recruiting
Est. primary completion 2026-12-31 · NCT03127631 · CT.gov ↗
What to watch
2027 (15)
January 2027 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseActive not recruiting
Est. primary completion 2027-01-28 · NCT03169985 · CT.gov ↗
What to watch
March 2027 (2)
April 2027 (1)
Phase 2/3Peripheral Nerve DiseaseNot yet recruiting
Est. primary completion 2027-04 · NCT07504198 · CT.gov ↗
What to watch
May 2027 (3)
Early phase / not applicableObesity & Overweight, Bariatric Surgery, Pharmacokinetics After Oral Intake, Drug AbsorptionNot yet recruiting
Est. primary completion 2027-05-15 · NCT07748273 · CT.gov ↗
What to watch
Phase 3Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2027-05-28 · NCT07619118 · CT.gov ↗
What to watch
Phase 1Primary Sclerosing Cholangitis, Inflammatory Bowel DiseasesRecruiting
Est. primary completion 2027-05-31 · NCT05912387 · CT.gov ↗
What to watch
June 2027 (3)
Phase 1Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05614739 · CT.gov ↗
What to watch
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2027-06-01 · NCT07629999 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseActive not recruiting
Est. primary completion 2027-06-01 · NCT05850091 · CT.gov ↗
What to watch
July 2027 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-07-30 · NCT07619131 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1Crohn's Ileocolitis, Crohn DiseaseRecruiting
Est. primary completion 2027-10-31 · NCT06538649 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-11-30 · NCT06488105 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Erectile Dysfunction Due to Arterial Disease, Atheroscleroses, Erectile Disfunction, Endothelial Dysfunction, Androgen Profile, TestosteroneRecruiting
Est. primary completion 2027-12 · NCT07460960 · CT.gov ↗
What to watch
Early phase / not applicableMelanomaRecruiting
Est. primary completion 2027-12 · NCT07704918 · CT.gov ↗
What to watch
2028 (10)
January 2028 (1)
Phase 3Venous Thromboembolism, Blood Clot, Post Thrombotic SyndromeRecruiting
Est. primary completion 2028-01 · NCT04319627 · CT.gov ↗
What to watch
March 2028 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2028-03-28 · NCT06856772 · CT.gov ↗
What to watch
April 2028 (1)
Phase 4Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer …Not yet recruiting
Est. primary completion 2028-04-21 · NCT07254221 · CT.gov ↗
What to watch
May 2028 (2)
Early phase / not applicableSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite AthletesEnrolling by invitation
Est. primary completion 2028-05-01 · NCT07568574 · CT.gov ↗
What to watch
Phase 2Clonal Cytopenia of Undetermined Significance, Myelodysplastic SyndromesRecruiting
Est. primary completion 2028-05-31 · NCT05483010 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2028-06-01 · NCT07474649 · CT.gov ↗
What to watch
September 2028 (2)
2029 (4)
February 2029 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2029-02-28 · NCT06186037 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic …Recruiting
Est. primary completion 2029-08-31 · NCT05832229 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2029-09 · NCT07799779 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Stroke, Cognitive DeclineRecruiting
Est. primary completion 2029-12-14 · NCT05155137 · CT.gov ↗
What to watch
2031 (4)
March 2031 (2)
July 2031 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2031-07 · NCT07232069 · CT.gov ↗
What to watch
September 2031 (1)
Phase 3Covert Brain InfarctionRecruiting
Est. primary completion 2031-09-30 · NCT07012629 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.